Purpose Poly (ADP-ribose) polymerase inhibitors (PARPi) have changed the management
of high-grade serous ovarian cancer (HGSOC). The rationale for the development of PARPi …

Abstract Background In Study 19, maintenance monotherapy with olaparib significantly
prolonged progression-free survival vs placebo in patients with platinum-sensitive, recurrent …

Background Ovarian cancer is the sixth most common cancer in women world‐wide.
Epithelial ovarian cancer (EOC) is the most common; three‐quarters of women present …

Background: Ovarian cancer remains the most common lethal gynecologic malignancy. The
therapeutic gains with the use of traditional cytotoxic chemotherapy in advanced stage …

Approximately 1% of women in the United States will be diagnosed with epithelial ovarian
cancer (EOC) during their lifetime. It is most likely to present at a more advanced stage …

Hydrogenolysis of cork has been examined using a range of precious metal catalysts
studying the effect of the support, added base and solvent used. The addition of a catalyst …

Olaparib is a poly (ADP‐ribose) polymerase enzyme inhibitor that is approved for use in
patients with advanced ovarian cancer (OC) and genetic BRCA1/2 mutations who have …

ASCO 2017—highlights of gynecological cancer | memo - Magazine of European Medical
Oncology Skip to main content SpringerLink Log in Menu Find a journal Publish with us …

The American Society of Clinical Oncology (ASCO) 2017 Annual Meeting was held again at
the McCormick Convention Center in Chicago, IL, USA. Over 37,500 international …

Background: Poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors have
entered into the clinic rapidly and are becoming a powerful therapeutic tool, especially in the …